Internal Neuromodulation Devices Market Revenue to Attain USD 42.07 Bn by 2033

30 Sep 2025

Share :

Table of Content

1. Internal Neuromodulation Devices Market Revenue and Trends 2025 to 2033 2. What are the major factors driving the market for internal neuromodulation devices? 3. Segment Insights: 4. Regional Insights: 5. Internal Neuromodulation Devices Market Coverage 6. Internal Neuromodulation Devices Market Key Players

Internal Neuromodulation Devices Market Revenue and Trends 2025 to 2033

The global internal neuromodulation devices market revenue reached USD 13.61 billion in 2025 and is predicted to attain around USD 42.07 billion by 2033 with a CAGR of 15.15%. This market is growing, as these devices are increasingly preferred over pharmacological treatments because many patients suffer from medication-resistant conditions.

What are the major factors driving the market for internal neuromodulation devices?

The internal neuromodulation devices market encompasses implantable devices used to manage chronic pain conditions. A key benefit of these devices is the potential to alleviate pain, which can also reduce the reliance on pain medications. Several factors are driving the market's expansion, including the increasing prevalence of chronic neurological diseases. Advancements in stimulation technologies and supportive reimbursement opportunities are also significant contributors. Furthermore, the growing acceptance and normalization of neurostimulation therapy are playing a crucial role in the market's growth trajectory.

Segment Insights:

• By device type, the spinal cord stimulators (SCS) segment dominated the market in 2024 due to their proven effectiveness in managing chronic pain conditions, a growing patient population, and increasing acceptance as a minimally invasive alternative to surgery. 
• By application/therapy area, the chronic pain management segment led the market with the largest share in 2024. This is due to the growing unmet need, along with strong clinical evidence demonstrating the effectiveness of neuromodulation therapies in managing chronic pain. 
• By technology/stimulation mode, the electrical stimulation segment dominated the market in 2024 due to its established effectiveness, safety, and versatility in treating a wide range of neurological and pain-related conditions. 
• By component, the implantable pulse generators segment led the internal neuromodulation devices market in 2024, as they are necessary for delivering electrical signals to patients, while also enabling longevity and programmability of the neuromodulation system. 
• By patient demographics, the adult patients segment dominated the market in 2024, as many of the current neuromodulation therapies (e.g., chronic pain, Parkinson's disease) are based on adult-onset or adult-persistent conditions. Chronic conditions, such as pain, neurological disorders, and movement impairments, are more prevalent in the adult population, supporting segmental growth.
• By end-user, the hospitals segment dominated the market in 2024, as hospitals are the primary setting for performing surgeries, implanting devices, and providing follow-ups and monitoring for internal neuromodulation therapy

Regional Insights:

North America dominated the internal neuromodulation devices market. This dominance is due to several factors. The region boasts robust healthcare systems and a high incidence of chronic neurological disorders. It also benefits from a skilled labor force and substantial investments in research and development. Furthermore, the reimbursement systems in North America support the adoption and use of neuromodulation technologies.

Asia Pacific is experiencing rapid growth in the market for internal neuromodulation devices. This expansion is fueled by increased healthcare investments across the region. There's also growing awareness and diagnosis of neurological and pain disorders. Additionally, the aging populations in countries like China, India, and Japan are driving demand. Regulatory reforms are also accelerating the adoption of medical devices and services, further boosting growth in the Asia Pacific market.

Internal Neuromodulation Devices Market Coverage

Internal Neuromodulation Devices Market Key Players

• Medtronic plc
• Abbott Laboratories
• Boston Scientific Corporation
• Nevro Corp.
• LivaNova PLC
• Axonics, Inc.
• NeuroPace, Inc.
• Nuvectra Corporation
• Aleva Neurotherapeutics SA
• Synapse Biomedical Inc.
• NeuroSigma, Inc.
• Inspire Medical Systems, Inc.
• Saluda Medical Pty Limited
• Mainstay Medical International plc
• Biotronik SE & Co. KG

Recent Development:

• In September 2024, Nevro Corp. announced FDA approval and a limited U.S. release of HFX iQ with HFX AdaptivAI, an AI-powered, personalized pain management platform for its spinal cord stimulation system. Leveraging clinical research and big data, it provides unprecedented and responsive relief for patients with chronic pain. (Source: https://www.prnewswire.com)

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/6896

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com |+1 804 441 9344